C2 PHARMA highlights importance of API quality, an in-Pharma Technologist Featured Story
When in-Pharma Technologist spoke to CEO of C2 PHARMA, Andrew Badrot, about the API business, instead of an established-against-pharmerging company debate, he framed it as an issue based around a quality-to-cost ratio. In the long-term, Badrot spelled out that he believes quality will win out.
Click here to view the article